Esperion Therapeutics Inc.

6.27-0.2800-4.27%Vol 646.19K1Y Perf -70.91%
Jun 28th, 2022 16:00 DELAYED
BID6.27 ASK6.67
Open6.46 Previous Close6.55
Pre-Market- After-Market6.58
 - -  0.31 4.94%
Target Price
11.22 
Analyst Rating
Hold 2.79
Potential %
78.95 
Finscreener Ranking
     40.01
Insiders Trans % 3/6/12 mo.
-50/-67/-67 
Value Ranking
★+     43.76
Insiders Value % 3/6/12 mo.
6/-4/-4 
Growth Ranking
★+     41.85
Insiders Shares Cnt. % 3/6/12 mo.
0/-10/-10 
Income Ranking
 —    -
Price Range Ratio 52W %
14.61 
Earnings Rating
Sell
Market Cap395.05M 
Earnings Date
2nd Aug 2022
Alpha-0.02 Standard Deviation0.17
Beta0.42 

Today's Price Range

6.086.69

52W Range

3.2823.75

5 Year PE Ratio Range

-6.40-7.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.74%
1 Month
12.93%
3 Months
38.19%
6 Months
33.13%
1 Year
-70.91%
3 Years
-85.92%
5 Years
-86.43%
10 Years
-

TickerPriceChg.Chg.%
ESPR6.27-0.2800-4.27
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.70
0.31
0.75
-3.50
Leverage Ratio -1.10
ProfitabilityValueIndustryS&P 500US Markets
78.10
-204.50
-203.80
-
-66.86
RevenueValueIndustryS&P 500US Markets
89.31M
1.42
-15.21
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.96-0.933.12
Q04 2021-2.32-1.7723.71
Q03 2021-2.86-2.628.39
Q02 2021-1.82-1.678.24
Q01 2021-2.08-3.50-68.27
Q04 2020-3.76-3.89-3.46
Q03 2020-3.52-3.0712.78
Q02 20202.134.32102.82
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.95-1.06Negative
9/2022 QR-0.93-14.81Negative
12/2022 FY-3.73-4.78Negative
12/2023 FY-2.05-7.89Negative
Next Report Date2nd Aug 2022
Estimated EPS Next Report-0.95
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume646.19K
Shares Outstanding63.01K
Shares Float44.41M
Trades Count7.34K
Dollar Volume4.13M
Avg. Volume1.00M
Avg. Weekly Volume932.10K
Avg. Monthly Volume881.21K
Avg. Quarterly Volume1.20M

Esperion Therapeutics Inc. (NASDAQ: ESPR) stock closed at 6.55 per share at the end of the most recent trading day (a 1.24% change compared to the prior day closing price) with a volume of 683.99K shares and market capitalization of 395.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 479 people. Esperion Therapeutics Inc. CEO is Timothy M. Mayleben.

The one-year performance of Esperion Therapeutics Inc. stock is -70.91%, while year-to-date (YTD) performance is 31%. ESPR stock has a five-year performance of -86.43%. Its 52-week range is between 3.28 and 23.75, which gives ESPR stock a 52-week price range ratio of 14.61%

Esperion Therapeutics Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 80.52, a price-to-sale (PS) ratio of 4.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.53%, a ROC of -194.99% and a ROE of 93.32%. The company’s profit margin is -66.86%, its EBITDA margin is -203.80%, and its revenue ttm is $89.31 Million , which makes it $1.42 revenue per share.

Of the last four earnings reports from Esperion Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.95 for the next earnings report. Esperion Therapeutics Inc.’s next earnings report date is 02nd Aug 2022.

The consensus rating of Wall Street analysts for Esperion Therapeutics Inc. is Hold (2.79), with a target price of $11.22, which is +78.95% compared to the current price. The earnings rating for Esperion Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Esperion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Esperion Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 0.42, CCI20 : 167.60, Chaikin Money Flow : 0.15, MACD : 0.13, Money Flow Index : 69.03, ROC : 7.38, RSI : 61.50, STOCH (14,3) : 95.53, STOCH RSI : 1.00, UO : 61.57, Williams %R : -4.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Esperion Therapeutics Inc. in the last 12-months were: Eric Warren (Sold 452 shares of value $2 427 ), J. Martin Carroll (Buy at a value of $28 180), Sheldon L. Koenig (Sold 5 694 shares of value $27 949 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (25.00 %)
2 (25.00 %)
3 (37.50 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
Hold
3 (37.50 %)
3 (37.50 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Summary RatingHold
2.79
Hold
2.79
Moderate Buy
2.54

Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

CEO: Timothy M. Mayleben

Telephone: +1 734 887-3903

Address: 3891 Ranchero Drive, Ann Arbor 48108, MI, US

Number of employees: 479

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

65%35%

Bearish Bullish

47%53%

TipRanks News for ESPR

Wed, 25 May 2022 09:10 GMT Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Kronos Bio (KRON) and Design Therapeutics (DSGN)

- TipRanks. All rights reserved.

Tue, 03 May 2022 15:55 GMT Esperion (ESPR) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Mon, 25 Apr 2022 16:05 GMT Esperion (ESPR) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 22:25 GMT Esperion (ESPR) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

News

Stocktwits